“
“BACKGROUND: The World Health Organization (WHO) has called for closer monitoring of bacille Calmette-Guerin (BCG) complications with specific efforts to distinguish BCG infection from tuberculosis.
OBJECTIVES: To detect the presence of BCG infection using clinical and microbiological approaches.
STUDY DESIGN: Between 2006 and 2008,32 cases, including 30 children with suspected
BCG-related complications and two adults with local skin infections, were referred to our laboratory. The definitive identification of the isolates was based on phenotypic and molecular testing. The genotype profile of the isolates was determined to evaluate the relatedness of the cases.
RESULTS: Molecular microbiological results confirmed the presence of infection due to Mycobacterium bovis LBH589 concentration BCG in 11 patients, of whom 9 were aged 2 months to 6 years and 2 were aged >40 years. Molecular fingerprinting revealed that all isolates were genetically related to each other and to M. bovis BCG Pasteur 1173P2.
CONCLUSION: A high incidence of adverse reactions to the BCG vaccine in the population studied clearly points to the need for a thorough study on the issue. We hope our study will be viewed as an evidence-based document for more precise
risk-benefit evaluation of BCG immunisation MRT67307 manufacturer in immunocompromised patients.”
“Although there are 23 generic levofloxacin (100 mg) tablets (LVFX tablets) and 1 brand name LVFX tablet (supply now discontinued) in Japan, there have been no reports that have evaluated and compared the dissolution profiles of LVFX tablets using the same dissolution method. We studied the dissolution profile of LVFX tablets by the Paddle method, a standard dissolution test method. Among 23 generic LVFX tablets, 2 LVFX tablets had lower dissolution rates and 14 had higher dissolution rates than the brand name LVFX tablet. It is suggested that LVFX tablets have different
dissolution profiles, which could cause different pharmacokinetic profiles.”
“BACKGROUND: A positive tuberculin skin test (TST) may indicate Galardin manufacturer cross-reacting immunity to non-tuberculous mycobacteria (NTM) and not latent tuberculosis infection (LTBI).
OBJECTIVES: To assess misclassification of LTBI, as assessed by skin testing with Mycobacterium avium sensitin (MaS), and to determine how this misclassification affects the analysis of risk factors for LTBI.
METHODS: In a population-based survey, participants underwent skin testing with M. tuberculosis purified protein derivative (PPD) and MaS. A PPD-dominant skin test was a reaction that was >= 3 mm larger than the MaS reaction; a MaS-dominant skin test was a reaction that was >= 3 mm larger than the PPD reaction.
RESULTS: Of 447 randomly selected persons, 135 (30%) had a positive PPD test. Of these, 21 (16%) were MaS-dominant, and were therefore attributable to NTM and misclassified as LTBI.